Delphi advisor to ProStrakan on Orexo transaction
Delphi has advised ProStrakan on the Orexo transaction in which distribution rights for the drug Abstral® are divided between Orexo and ProStrakan. The value of the transaction is just over SEK 600 million. “It has been incredibly rewarding and interesting to work with ProStrakan on such a major transaction in this important area” says Johan Hübner, partner at Delphi.